Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Down 5.2% in September

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) was the recipient of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 10,190,000 shares, a decrease of 5.2% from the September 15th total of 10,750,000 shares. Based on an average daily volume of 577,600 shares, the days-to-cover ratio is currently 17.6 days. Currently, 15.7% of the shares of the company are sold short.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on KURA. HC Wainwright reaffirmed a "buy" rating and set a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. Wedbush reaffirmed an "outperform" rating and set a $37.00 price target on shares of Kura Oncology in a research note on Friday, August 9th. StockNews.com cut shares of Kura Oncology from a "hold" rating to a "sell" rating in a research note on Thursday, August 22nd. JMP Securities reaffirmed a "market outperform" rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Monday, August 12th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Kura Oncology in a research note on Monday, September 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Kura Oncology has a consensus rating of "Moderate Buy" and an average price target of $29.20.

Kura Oncology Price Performance

Shares of Kura Oncology stock traded down $0.18 during trading hours on Thursday, hitting $18.09. The company's stock had a trading volume of 295,354 shares, compared to its average volume of 905,960. The business has a 50 day moving average price of $19.55 and a two-hundred day moving average price of $20.23. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17. The company has a market cap of $1.38 billion, a PE ratio of -8.43 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.04. Kura Oncology's quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.53) EPS. Analysts expect that Kura Oncology will post -2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KURA. Susquehanna Fundamental Investments LLC bought a new stake in Kura Oncology during the 1st quarter valued at $507,000. Hennion & Walsh Asset Management Inc. grew its position in Kura Oncology by 42.3% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 181,674 shares of the company's stock worth $3,875,000 after purchasing an additional 54,031 shares during the period. Assenagon Asset Management S.A. grew its position in Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company's stock worth $35,653,000 after purchasing an additional 577,732 shares during the period. Vanguard Group Inc. grew its position in shares of Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company's stock valued at $86,726,000 after acquiring an additional 28,212 shares during the period. Finally, Sofinnova Investments Inc. grew its position in shares of Kura Oncology by 64.4% during the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company's stock valued at $16,992,000 after acquiring an additional 323,303 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.